New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
BARCELONA, Spain, July 3, 2017 /PRNewswire/ -- SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided pri...
Metastatic Colorectal Cancer Patients Treated First-line with SIR-Spheres(R) Y-90 Resin Microspheres More Likely to Become Candidates for Potentially Curative Liver Surgery, REsect Study Shows
MAINZ, Germany, May 24, 2017 /PRNewswire/ -- Surgeons' blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12th Annual European-African HPB meeting. Adding selective internal...
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
AMSTERDAM, April 24, 2017 /PRNewswire/ -- 459-patient SARAH Study shows that local treatments of advanced or inoperable Hepatocellular Cancer (HCC) with SIR-SpheresY-90 resin microspheres did not lead to a planned superiority difference in overall survival compared to daily standard-of-care sys...
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
SYDNEY, Oct. 11, 2016 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90 ) microspheres as an option in for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of ...
Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres(R) Y-90 resin microspheres, New SIRFLOX Analysis Shows
BARCELONA, Spain, July 1, 2016 /PRNewswire/ -- New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology's 18th World Congress on Gastrointestinal Cancer suggest that patients with liver-dominant mCRC treated first-line with the combi...
SIR-Spheres(R) Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
LONDON, March 31, 2016 /PRNewswire-FirstCall/ -- Sirtex (ASX: SRX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB)[1] stating that NHS doctors and commissioners may consider SIR-SpheresY-90 resin microspheres ...
Netherlands Healthcare Institute Approves Reimbursement of Selective Internal Radiation Therapy (SIRT) for Patients with Colorectal Liver Metastases Who Have Failed Prior Treatment
BONN, Germany, March 17, 2016 /PRNewswire/ -- Sirtex (ASX: SRX) announced that the Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed on or are intole...
SIRFLOX Study Published in Journal of Clinical Oncology
SYDNEY, Feb. 23, 2016 /PRNewswire-FirstCall/ -- Sirtex Medical Limited (ASX: SRX) announced that the results of the SIRFLOX study with SIR-SpheresY-90 resin microspheres have been published on-line in the Journal of Clinical Oncology (JCO), the leading peer-reviewed publication of the American So...
Treatment Results of SIR-Spheres® Y-90 Resin Microspheres are Similar Regardless of Patient Age, New Publication Shows
SYDNEY, Jan. 20, 2016 /PRNewswire/ -- 606-patient MORE Study Sub-Group Analysis Examined Outcomes for Elderly (≥70 years) and Very Elderly (≥75 years) Patients with Liver-Dominant Metastatic Colorectal Cancer (mCRC) A new analysis of the MORE data on 606 mCRC patients treated with SIR-Spheres Y-...
SIRFLOX Study Presented at ASCO 2015 Annual Meeting
CHICAGO, June 1, 2015 /PRNewswire/ -- The benefits of adding liver-directed SIR-SpheresY-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Soci...
Sirtex Reports Preliminary SIRFLOX Study Results
SYDNEY, March 23, 2015 /PRNewswire/ -- * In the first-line treatment of non-resectable metastatic colorectal cancer: * SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival. * SIRFLOX study does show a statistically significant improvem...
Sirtex Reports Preliminary SIRFLOX Study Results
SYDNEY, March 17, 2015 /PRNewswire/ -- * In the first-line treatment of non-resectable metastatic colorectal cancer: * SIRFLOX study does not show a statistically significant improvement in overall Progression-Free Survival. * SIRFLOX study does show a statistically significant improvement ...
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
SYDNEY, Jan. 30, 2015 /PRNewswire/ -- Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres®Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC) Sir...
